When was TearSolutions founded?

TearSolutions was founded in 2013 and raised its 1st funding round 1 year after it was founded.

Where is TearSolutions located?

TearSolutions is headquartered in Charlottesville, United States.

Who is the current CEO of TearSolutions?

Mark Logan of TearSolutions. They are also an angel investors in 1 startup.

How many employees does TearSolutions have?

As of Jul 31, 2026, the latest employee count at TearSolutions is 10.

Is TearSolutions a funded company?

TearSolutions is a funded company, having raised a total of $43M across 11 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jun 25, 2014.

When was the latest funding round of TearSolutions?

TearSolutions' latest funding was a $***** Series B round on Oct 29, 2025, with participation from 0 investor. Its primary sector is Ophthalmology. In United States, the Ophthalmology sector has seen $1.46B in funding in 2026 to date.

Where does TearSolutions rank among its competitors?

TearSolutions ranks 6th amongst 56 active competitors, of which 17 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Biophytis, which secured $1.58M in Mar, 2026.

Who are the top competitors of TearSolutions?

TearSolutions' top competitors include Lineage Cell Therapeutics, Remegen and Stellular Bio. Among them, Biophytis secured the most recent funding round in March, 2026.

TearSolutions - 2026 Company Profile, Team, Funding & Competitors

Company Details

TearSolutions develop topical therapeutics for the treatment of dry eye disease. Its lead product is a proprietary synthetic fragment of the protein lacritin. The company claims that Lacripep is equipotent with natural lacritin and can alleviate dry-eye symptoms for up to 16 hours. Its currently in phase I clinical trials.

Website: tearsolutions.com
Email ID: *****@tearsolutions.com

Key Metrics

Founded Year

2013

Location

Charlottesville, United States

Stage

Series B

Total Funding

$43M in 11 rounds

Latest Funding Round

Series B, Oct 29, 2025, $*****

Investors

Center for Innovative Technology & 6 more

Ranked

6^th among 56 active competitors

Employee Count

10 as on Jul 31, 2026

Similar Companies

Lineage Cell Therapeutics & 55 more

View TearSolutions' full profile

TearSolutions has raised a total funding of $43M over 11 rounds. Its first funding round was on Jun 25, 2014. TearSolutions has 7 institutional investors.

Here is the list of recent funding rounds of TearSolutions:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 29, 2025	3054517	Series B	2957412	1892463	3883816	9190951
Sep 25, 2024	8138489	Series B	6935349	7589699	5141260	6608036
Sep 08, 2023	6631122	Series B	4107987	4481061	2536363	8461637

Access funding benchmarks and valuations. Sign up today!

View details of TearSolutions's funding rounds and investors

The founders of TearSolutions are Mark Logan and Gordon Laurie.

Here are the details of TearSolutions' key team members:

Mark Logan: Co-Founder & CEO of TearSolutions. They are also an angel investor in 1 startup and serve on the board of 1 company.
Contact Info: 1 email address
Gordon Laurie: Co-Founder of TearSolutions.
Contact Info: 1 email address

View details of TearSolutions's Founder profiles and Board Members

TearSolutions' employee count trend

TearSolutions has 10 employees as of Jul 26. Here is TearSolutions's employee count trend over the years:

Uncover TearSolutions' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of TearSolutions include Lineage Cell Therapeutics, Remegen and Stellular Bio. Here is the list of Top 10 competitors of TearSolutions, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Lineage Cell Therapeutics 1990, Carlsbad (United States), Public	Developer of cell based therapies for the treatment of cancer, eye disease and spinal disorders	$45.8M	State of California, Juvenescence & 4 others	66/100
2nd	Remegen 2008, Yantai (China), Public	Developer of therapies for the treatment of cancer, autoimmune and eye diseases	$100M	Lilly Asia Ventures, CDG Capital & 10 others	61/100
3rd	Stellular Bio 2014, Watertown (United States), Series A	Developer of a platform for producing allogeneic, stem-cell-derived platelet-like cells	$37.5M	Qiming, Vivo Capital & 5 others	59/100
4th	Biophytis 2006, Romainville (France), Public	Developer of drugs for neuromuscular and age-related diseases	$2.6M	Kreos Capital, Seventure Partners & 1 others	56/100
5th	Valitor 2010, Berkeley (United States), Series B	Developer of therapeutic proteins for multiple disease conditions	$38.2M	Morningside, ShangPharma Innovation & 9 others	55/100
6th	TearSolutions 2013, Charlottesville (United States), Series B	Topical therapeutics for the treatment of dry eye disease	$43M	Center for Innovative Technology, VTC Ventures ... & 5 others	54/100
7th	Azura Ophthalmics 1997, Tel Aviv (Israel), Series C	Developing therapies for meibomian gland dysfunction	$37.2M	Orbimed, Medical Research Commercialisation Fund ... & 4 others	53/100
8th	Retrotope 2006, Los Altos (United States), Acquired	Developer of therapeutics to treat neurodegenerative and ophthalmological diseases	$69.6M	SDL Ventures, Green Park & Golf Ventures ... & 12 others	53/100
9th	Marinomed 2006, Vienna (Austria), Public	Developer of drugs for immunology, allergy and infectious diseases	-	Invest, aws Mittelstandsfonds & 4 others	53/100
10th	Stuart Therapeutics 2017, Stuart (United States), Series A	Developer of therapies for treating ophthalmic, gastrointestinal, inflammatory disorders	$11M	InFocus Capital Partners, BioBrit & 2 others	51/100